Lionsgate Studios Corp. (LION) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to a loss of $0.31 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -42.86%. A quarter ago, it was expected that this company would post a loss of $0.12 per share when it actually produced a loss of $0.32, delivering a surprise of -166.67%.Over the last four quarters, the company ...

LANTHEUS DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages Lantheus Holdings, Inc. Investors to Secure Counsel Before Important November 10 Deadline in Securities Class Action - LNTHNovember 06, 2025 9:25 PM EST | Source: The Rosen Law Firm PANew York, New York--(Newsfile Corp. - November 6, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025, both dates incl ...

If you thought our angle on this company was interesting, you may want to check out our idea room, The Value Lab . We focus on long-only value ideas of interest to us, where we try to find international mispriced equities and target a portfolio yield of about 4% . We've done really well for ourselves over the last 5 years, but it took getting our hands dirty in international markets. If you are a value-investor, serious about protecting your wealth, our gang could help broaden your horizons and give some in ...

Shares of Huntsman ( HUN ) have been a very poor performer over the past year, losing over 60% of their value. It has, quite simply, been a brutal macro environment for the chemicals sector, facing weak construction activity and meaningful excessOver fifteen years of experience making contrarian bets based on my macro view and stock-specific turnaround stories to garner outsized returns with a favorable risk/reward profile. If you want me to cover a specific stock or have a question for an article, just let ...

Shares of Huntsman ( HUN ) have been a very poor performer over the past year, losing over 60% of their value. It has, quite simply, been a brutal macro environment for the chemicals sector, facing weak construction activity and meaningful excessOver fifteen years of experience making contrarian bets based on my macro view and stock-specific turnaround stories to garner outsized returns with a favorable risk/reward profile. If you want me to cover a specific stock or have a question for an article, just let ...

公司股价与市场表现 - RBC Capital设定目标股价为45美元，较当前27.50美元有约63.64%的潜在上涨空间 [1][5] - 公司当前股价为27.50美元，日内上涨12.61%（3.08美元），交易区间在24.93美元至28.60美元之间 [4] - 公司市值为约22.3亿美元，当日成交量为486万股 [4] 公司财务状况与前景 - 成功的融资交易使公司有望在无需进一步股份稀释的情况下实现盈利 [2][5] - 财务稳定性的增强使公司能更专注于核心业务活动，无需筹集额外资金 [2] 行业竞争格局 - 罗氏药物Enspryng在甲状腺眼病治疗的三期临床试验结果令人失望，减轻了对公司产品veligrotug和VRDN-003的竞争压力 [3][5] - 这一进展可能增强公司在甲状腺眼病治疗市场的地位，并潜在增加其市场份额 [3]

Free Newsletter Get the hottest Fintech Hong Kong News once a month in your Inbox Stripe and NEC Corporation have begun exploring the integration of the Stripe Reader S700 payment terminal, part of the unified commerce solution Stripe Terminal, with NEC’s face recognition payment service.The collaboration aims to combine Stripe’s payment infrastructure with NEC’s facial recognition technology, known for its high authentication accuracy*, to enable secure, hands-free payments and improve customer conveni ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Zacks Thematic Screens lets you dive into 30 dynamic investment themes shaping the future. Whether you're interested in cutting-edge technology, renewable energy, or healthcare innovations, our themes help you invest in ideas that matter to you.Let’s take a closer look at the Artificial Intelligence theme and analyze a hot stock that the screen returned, namely Palantir (PLTR) .Artificial Intelligence Artificial Intelligence (AI) refers to the technology that enables computers and machines to simulate human ...

Coherus Oncology (CHRS) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -3.13%. A quarter ago, it was expected that this drug developer would post a loss of $0.31 per share when it actually produced a loss of $0.34, delivering a surprise of -9.68%.Over the last four quarters, the company ha ...